Press-release for stocks for nvcn

Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
Published: 2021-11-01 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3851.32% | O: -0.99% H: 6.31% C: 2.33%
financial results results

Neovasc Reducer™ Featured in Polish Heart Journal
Published: 2021-10-21 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3851.32% | O: -1.32% H: 1.33% C: -1.32%
heart

Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
Published: 2021-09-23 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3904.0% | O: -0.52% H: 0.52% C: -0.39%
conference

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
Published: 2021-09-16 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3970.21% | O: 15.11% H: 1.12% C: -9.04%
fda fda approval trial approval

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
Published: 2021-08-17 (Crawled : 13:15) - biospace.com/
NVCN | $30.03 1.66% -2.02% 0

| 3713.82% | O: 1.6% H: 0.22% C: -6.33%
fda submission

Neovasc Announces New Appointments in Regulatory and Clinical Leadership
Published: 2021-07-13 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3255.31% | O: 3.91% H: 0.0% C: -5.96%

Neovasc to Sponsor Symposium on Reducer at EuroPCR
Published: 2021-05-13 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3800.0% | O: 5.1% H: 0.7% C: -8.61%
symposium

Neovasc Provides Reducer Reimbursement Progress Update
Published: 2021-04-28 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0

| 3095.02% | O: -1.05% H: 5.83% C: 5.34%

Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
Published: 2021-04-27 (Crawled : 13:15) - globenewswire.com
NVCN | $30.03 1.66% -2.02% 0